Quest Diagnostics saw robust growth in earnings and revenue, surpassing expectations for Q4 2024. Overall, Quest had a successful quarter, driven by strategic acquisitions and advancements in its ...

Shares of Quest Diagnostics Inc. DGX slid 2.87% to $168.15 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.76% to 5,572. ...

Explore Quest Diagnostics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for DGX. Grail shares are trading higher Wednesday after the company announced a ...

Quest Diagnostics DGX recently announced a strategic ... and venture capital investments further fuel this sector. AI tools enhance imaging accuracy and speed, aiding oncology professionals ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Cash flow from operations fell by 18.9%, showing underlying operational challenges. Quest Diagnostics is a leading provider of diagnostic tests -- ranging from allergies to cancer -- in the United ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In the last three months, 11 analysts have published ratings on Quest Diagnostics (NYSE:DGX), offering a diverse range of perspectives from bullish to bearish. The table below provides a concise ...

Shares of Grail (NASDAQ:GRAL) shot up 33% Thursday, the day after the company announced a partnership with Quest Diagnostics (DGX) to expand provider access to Grail's Galleri multi-cancer early ...